Key Insights
- Johnson & Johnson MedTech partners with Pacira BioSciences to co-promote ZILRETTA®, an extended-release injectable therapy for knee osteoarthritis pain.
- The agreement strengthens J&J’s Early Intervention portfolio, aligning with its mission to reduce reliance on surgery and opioids.
- With over 30 million U.S. adults affected by osteoarthritis, the collaboration targets a high-burden, underserved market.
Expanding Non-Surgical Pathways
Through this agreement, Johnson & Johnson MedTech integrates ZILRETTA® into its Early Intervention offerings. The therapy, leveraging proprietary microsphere technology for extended pain relief, represents a crucial option for patients before considering invasive procedures.
Addressing a Growing Public Health Challenge
Osteoarthritis of the knee remains one of the most debilitating musculoskeletal conditions, limiting mobility and quality of life. By promoting non-surgical, sustained-pain relief solutions, J&J and Pacira aim to reach millions of patients earlier in the treatment pathway, potentially reducing healthcare costs tied to late-stage interventions.
Strategic Synergy with Pacira’s Leadership in Pain Management
Pacira, known for advancing non-opioid pain therapies, complements J&J MedTech’s expertise in orthopaedics and enabling technologies. The collaboration includes shared professional education and engagement initiatives, amplifying awareness among clinicians and patients.
Shaping the Future of Orthopaedic Care
This deal underscores J&J MedTech’s broader push to keep people moving by offering comprehensive orthopaedic solutions—from robotics and joint reconstruction to early intervention therapies. By embedding ZILRETTA® into its ecosystem, J&J signals its intent to lead the shift toward patient-centric, non-invasive orthopaedic care.
By
